Kanamori Y, Kigawa J, Minagawa Y, Irie T, Itamochi H, Cheng X, Okada M, Terakawa N
Department of Obstetrics and Gynecology, Tottori University School of Medicine, Nishimachi, Yonago, Japan.
Gynecol Obstet Invest. 1997;44(1):57-60. doi: 10.1159/000291411.
We evaluated 3 patients with advanced cervical cancer treated with cisplatin intra-arterially and intravenously. The dose of cisplatin was 50 mg/m2 in each infusion. Chemotherapy was repeated at 4-week intervals for three to four courses. The clinical response and the tumor concentration of platinum were evaluated in each course. All patients who received the intra-arterial infusion of cisplatin were judged to be responders, whereas none of them responded to the intravenous infusion. The platinum concentration in tumor tissue was significantly higher after intra-arterial infusion of cisplatin (1.97 +/- 0.04 vs. 2.86 +/- 0.10 microg/g). Although there were no apparent differences in side effects between intra-arterial and intravenous routes, 2 of 3 patients rejected an intra-arterial route. The present study suggests that intra-arterial administration of cisplatin may be useful in treating locally advanced cervical cancer.
我们评估了3例接受顺铂动脉内和静脉内治疗的晚期宫颈癌患者。每次输注顺铂的剂量为50mg/m²。化疗每4周重复一次，共进行三到四个疗程。在每个疗程中评估临床反应和铂的肿瘤浓度。所有接受顺铂动脉内输注的患者均被判定为有反应者，而他们中没有人对静脉输注有反应。顺铂动脉内输注后肿瘤组织中的铂浓度显著更高（1.97±0.04对2.86±0.10μg/g）。尽管动脉内和静脉内途径在副作用方面没有明显差异，但3例患者中有2例拒绝动脉内途径。本研究表明，顺铂动脉内给药可能对治疗局部晚期宫颈癌有用。
